RedHill Biopharma (RDHL) Current Assets (2012 - 2025)

RedHill Biopharma (RDHL) has reported Current Assets for 14 consecutive years, with $6.5 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Current Assets fell 45.19% year-over-year to $6.5 million in Q4 2025; TTM through Dec 2025 was $6.5 million, a 45.19% decrease from a year earlier, with the FY2025 full-year figure at $6.5 million, down 45.19% from the prior year.
• Current Assets was $6.5 million for Q4 2025 at RedHill Biopharma, down from $12.6 million in the prior quarter.
• Over five years, Current Assets peaked at $98.5 million in Q2 2021 and troughed at $6.5 million in Q4 2025.
• A 5-year average of $45.5 million and a median of $21.6 million in 2023 frame the typical range for Current Assets.
• Across the five-year window, Current Assets surged 61.13% in 2021 and plunged 81.21% in 2023, its largest moves.
• Over 5 years, Current Assets stood at $89.2 million in 2021, then declined by 3.65% to $85.9 million in 2022, then sank by 81.21% to $16.1 million in 2023, then retreated by 26.2% to $11.9 million in 2024, then plunged by 45.19% to $6.5 million in 2025.
• The last three Current Assets figures came in at $6.5 million (Q4 2025), $12.6 million (Q2 2025), and $11.9 million (Q4 2024), per Business Quant data.